Form 4: Arbutus Biopharma Director Acquires Stock Options

Director Daniel D. Burgess of Arbutus Biopharma Corporation acquired stock options for 67,000 common shares at an exercise price of $3.28 on May 23, 2024.

Summary

• On May 23, 2024, Daniel D. Burgess, a director of Arbutus Biopharma Corporation, was granted stock options.
• The options give him the right to buy 67,000 common shares of Arbutus Biopharma.
• The exercise price for these options is $3.28 per share.
• The options are fully vested and exercisable as of the grant date.
• The options expire on May 23, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) which is generally viewed neutrally to positively as it incentivizes the director. There are no red flags or negative implications apparent.

Positives

• The options are fully vested and exercisable as of the date of the grant, providing immediate benefit to the director.

Future Outlook

NA

Industry Context

This is a standard practice for compensating and incentivizing board members in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biopharmaceutical industry.
• The vesting schedule and exercise price are typical for such grants, often aligning with market prices at the time of the grant.
• Companies like Gilead Sciences, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, incentivizing them to work towards increasing shareholder value.

Key Dates